1,196 results on '"Parving, H.-H."'
Search Results
2. Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia—the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)
3. Insulin analogues and severe hypoglycaemia in type 1 diabetes
4. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes
5. Effect of insulin degludec vs insulin glargine U100 on occurrence of nocturnal hypoglycaemia assessed by plasma glucose profiles in people with type 1 diabetes: HypoDeg trial
6. ACTH stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia
7. Effect of insulin degludec versus insulin glargine u100 on occurrence of cgm-recorded nocturnal hypoglycaemia in people with type 1 diabetes and previous nocturnal severe hypoglyceamia
8. The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1
9. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria:An IRMA2 sub-study
10. Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12 year follow-up study
11. SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes
12. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials
13. The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy
14. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
15. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
16. Supplement to: Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
17. A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus
18. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes
19. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial
20. Telomere length predicts all-cause mortality in patients with type 1 diabetes
21. The Importance of Short-Term Off-Target Effects in Estimating the Long-Term Renal and Cardiovascular Protection of Angiotensin Receptor Blockers
22. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial
23. Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy
24. Long-term prevention of diabetic nephropathy: an audit
25. Increased renal gene transcription of protein kinase C-β in human diabetic nephropathy: relationship to long-term glycaemic control
26. Comparison of Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycaemia
27. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes
28. Anaemia in diabetes: is there a rationale to TREAT?
29. Association between severe diabetic retinopathy and lectin pathway proteins – an 18-year follow-up study with newly diagnosed type 1 diabetes patients
30. COMPARISON OF INSULIN DEGLUDEC AND GLARGINE U100 IN PATIENTS WITH TYPE 1 DIABETES PRONE TO SEVERE NOCTURNAL HYPOGLYCAEMIA
31. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients
32. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study
33. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications
34. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy
35. Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate
36. Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes
37. Total plasma homocysteine is associated with hypertension in Type I diabetic patients
38. Controlling hypertension in diabetes
39. Pregnancy and progression of diabetic nephropathy
40. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective
41. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients
42. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study
43. Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes
44. Evaluation of placental growth factor and soluble Fms-like tyrosine kinase 1 as predictors of all-cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy
45. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy
46. Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme
47. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
48. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril
49. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment
50. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.